SLC2A1 and neoplasm: reported the benefits of overexpressing GLUT1 in CAR T-cells, including increased proliferative capacity and persistence in low-glucose conditions, increased proportions of stem cell-like memory T-cells after repeated tumor challenge, upregulation of genes involved in glycolysis and oxidative phosphorylation, and improved anti-tumor activity in vitro and in vivo in models of both leukemia and solid tumors, including RCC and glioblastoma.